background image

Paid Clinical Trials Gilbert

Discover 1,256 paid clinical trials in Gilbert, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

for
Metastatic Castration-resistant Prostate Cancer
Location: 40 recruiting locations
Sponsor: Celgene

Sex: Male

Age: 18+

Code: NCT06764485

Phase3, Recruiting
Active & Responsive

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

for
Metastatic Breast Cancer
Location: 54 recruiting locations
Sponsor: American Society of Clinical Oncology

Sex: All

Age: 65+

Code: NCT06377852

Phase3, Recruiting
Active & Responsive

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

for
Solid Tumor, Adult, Colorectal Cancer,
Location: 13 recruiting locations
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT04981119

Recruiting
Active & Responsive

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for
Breast Cancer
Location: 120 recruiting locations
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: 12 recruiting locations
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06051695

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: 34 recruiting locations
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06297226

Phase2, Recruiting
Active & Responsive

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for
Carcinoma, Non-Small-Cell Lung
Location: 40 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06623422

Phase3, Recruiting
Active & Responsive

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

for
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma,
Location: 16 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05458297

Phase2, Recruiting
Active & Responsive

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

for
Leukemia, Myeloid, Acute
Location: 21 recruiting locations
Sponsor: OncoVerity, Inc.

Sex: All

Age: 18+

Code: NCT06384261

Phase2, Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: 10 recruiting locations
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase1, Phase2, Recruiting